January 23, 2025 03:01 PM EST
Pharma
Law

Pur­due, Sack­lers reach new $7.4B opi­oid set­tle­ment af­ter SCO­TUS re­jec­tion

Nicole DeFeudis

Editor

Pur­due Phar­ma and the Sack­ler fam­i­ly have agreed to a $7.4 bil­lion set­tle­ment in a long­stand­ing le­gal bat­tle over the na­tion’s opi­oid epi­dem­ic.

The deal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bio­Marin turns to ex-Roche deal­mak­er James Sabry to build ‘next ver­sion’ of 27-year-old com­pa­ny

As an­oth­er Trump term gets un­der­way, phar­ma ad­vi­sors get com­fort­able with un­cer­tain­ty

Sam­sung Bio hits rev­enue high, se­cures largest con­tract to date

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

Ab­b­Vie part­ners with Neo­morph in lat­est mol­e­c­u­lar glue deal

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times